~~<i id='B211A5646B'><strike id='B211A5646B'><tt id='B211A5646B'><pre id='B211A5646B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：comprehensive 2025-09-30 17:03:39 - browse：5451

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： 5 takeaways from STAT's examination of Zynex Medical

entertainment

leisure time

knowledge

leisure time

explore

ErosDervishiforSTATBrittHermesonceconsideredherselfadoctor.Now,she’sanapostate.Hermesspentthreeyears

WSS

Experts study whether long Covid risk adds up with each reinfection

Lawsuit highlights wrinkle for disputes over surprise medical bills

'Essentially witchcraft:' A former naturopath takes on the field

Curing rare childhood diseases will falter unless Congress steps up

What will Novo Nordisk's VC do with its influx of cash?

With Roe v Wade overturned, abortion providers work to adapt

hotspot

comprehensive

entertainment

Sports medicine is finally prioritizing gender equality

Medicare innovation center doesn’t save money, experts say

Peter Hotez and the public health issue of online harassment

How faith leaders like me can help address America's obesity epidemic

Medical leaders decry Supreme Court decision on affirmative action

Cheap, fast test for Zika and dengue could cost just $1

At least 13 dead in Texas as scorching temps continue

6 solutions to address cancer drug shortages and others

Supreme Court strikes down use of affirmative action

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

entertainment

The United States is paying nearly triple for new Covid vaccines

Congress extends some pandemic preparedness programs

5 takeaways from STAT's examination of Zynex Medical

Flu, Covid vaccination rates decline, new survey data show

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

European officials brace for rough respiratory virus season

leisure time

knowledge

leisure time

explore